Datapoint: Gilenya Patent Upheld in Appeals Court

Novartis scored a major patent victory for its multiple sclerosis drug, Gilenya, this week. A federal appeals court on Tuesday upheld a dosage regimen patent for the sphingosine 1-phosphate receptor modulator, granting Novartis a permanent injunction against generic challenger HEC Pharma. The patent is currently set to expire in 2027. For the treatment of multiple sclerosis, 25% of all insured lives have unrestricted access to Gilenya under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/5/2022

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 8

Datapoint: Humana to Shutter SeniorBridge

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 7

Datapoint: Rigel’s New AML Drug Will Face Off Against Tibsovo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: United Projects 9% MA Growth in 2023

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today